Flow Cytometry Shared Service

16.0摘要：流式细胞仪共享服务 流式细胞术共享服务（FCSS）为马里兰州大学的研究人员提供了Marlene和 Stewart Greenebaum综合癌症中心（UMGCCC）提供支持研究的基本服务 免疫学和癌症生物学需要流式细胞术和分析（光谱和质谱细胞术） 和细胞分选能力。FCSS提供方便的访问成本效益和高质量的服务 由专家管理。FCSS是巴尔的摩/华盛顿地区的第一个设施， 光谱细胞仪两台Helios质量细胞仪可同时测量 大量的参数（当前>50个参数/细胞），具有最小补偿。使用新的- 第二代Cytek Aurora光谱流式细胞仪，FCSS已经开发了内部23色和30色 使用板即插即用免疫表型分型。MoFlo Astrios高级细胞分选仪能够 在BSL-2控制下同时分选六个种群。Miltenyi MACSQuant分析仪10容纳在 该空间仅供FCSS工作人员使用，用于分析CAR-T细胞治疗的临床样本 在我们的Fannie Angelos细胞治疗GMP实验室开发。这些最先进的 仪器提供了研究免疫学和癌症生物学的创新方法， 临床试验FCSS由具有数十年流程操作经验的技术专家组成 细胞计数器/分选器和质谱细胞计数器。参加社联主任每月讲座的有： 附近的学术机构，医院和生物技术公司的成员，讲座广泛 被认为是一个很好的教育资源。由FCSS用户组成的内部科学咨询委员会提供 为FCSS提供指导，并帮助制定新设备和技术的战略规划。FCSS提供 轻松获得流式细胞仪服务。癌症中心的研究人员与同行评审的资金优先。 FCSS服务具有很高的成本效益，因为其收费结构与其他学术和商业服务相比具有竞争力。 癌症中心的会员可获25%的补助金。FCSS的使用率很高。在 2019年，FCSS支持了90名研究者的研究，其中42名（46.7%）是UMGCCC成员。FCSS 在供资总额中支持了6 240万美元。这笔资金中有2730万美元与癌症有关，所有这些都是同行 综述2015年至2019年，FCSS支持了213份与癌症相关的出版物，包括在 高影响力的期刊，如PNAS，Nature和Nature Communications。

16.0 Abstract: Flow Cytometry Shared Service The Flow Cytometry Shared Service (FCSS) provides investigators at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) with essential services that support research in immunology and cancer biology requiring flow cytometry and with analytical (spectral and mass cytometry) and cell sorting capabilities. FCSS provides convenient access to cost-effective and high-quality services managed by expert staff. FCSS was the first facility in the Baltimore/Washington area with both mass and spectral cytometry instrumentation. The two Helios mass cytometers enable simultaneous measurement of large numbers of parameters (currently >50 parameters/cell) with minimum compensation. Using the new- generation Cytek Aurora spectral cytometers, FCSS has developed in-house 23- and 30-color immunophenotyping plug-and-play use panels. The MoFlo Astrios advanced cell sorter provides the ability to simultaneously sort six populations under BSL-2 containment. A Miltenyi MACSQuant Analyzer 10 is housed in this space which is only accessible to FCSS staff and is used to analyze clinical samples for CAR-T cell therapy developed in our Fannie Angelos GMP Laboratory for Cellular Therapeutics. These state-of-the-art instruments offer innovative approaches to study immunology and cancer biology and to monitor novel clinical trials. FCSS is staffed by technical experts with decades of experience in the operation of flow cytometers/sorters and mass cytometers. The monthly lectures presented by the FCSS director are attended by nearby members of academic institutions, hospitals, and biotech companies, and the lectures are widely considered a great educational resource. An internal scientific advisory board consisting of FCSS users provides guidance to FCSS and helps develop strategic planning for new equipment and technologies. FCSS provides easy access to flow cytometry services. Cancer Center investigators with peer-reviewed funding are prioritized. FCSS services are highly cost-effective, as the fee structure is competitive with other academic and commercial sources, and a 25% UMGCCC-funded subsidy is given to Cancer Center members. FCSS is highly utilized. In 2019, FCSS supported studies by 90 total investigators, 42 (46.7%) of whom were UMGCCC members. FCSS supported $62.4 million of total funding. $27.3 million of this funding was cancer-related, all of which was peer reviewed. FCSS supported 213 cancer-related publications from 2015 to 2019, including those published in such high-impact journals as PNAS, Nature, and Nature Communications.